Drug
HS 10541
HS 10541: highest development phase Phase 1, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10541 NCT07615413 | Phase 1 | KRAS G12C Mutation Advanced Solid Tumor |
Latest
No recent events.
Follow HS 10541 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.